Clinical Research Papers:

Percutaneous computed tomography-guided cryoablation for recurrent retroperitoneal soft tissue sarcoma: a study of safety and efficacy

Wenzhe Fan, Lizhi Niu, Yu Wang, Yingqiang Zhang, Xuehua Yao, Guosheng Tan, Jianyong Yang and Jiaping Li _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:42639-42649. https://doi.org/10.18632/oncotarget.9476

Metrics: PDF 992 views  |   HTML 1522 views  |   ?  


Wenzhe Fan1, Lizhi Niu2,3, Yu Wang1, Yingqiang Zhang1, Xuehua Yao1, Guosheng Tan4, Jianyong Yang4,5, Jiaping Li1

1Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

2Fuda Cancer Hospital, Guangzhou, China

3Fuda Institute of Cryosurgery for Cancer, Guangzhou, China

4Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

5Department of Medical Imaging, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

Correspondence to:

Jia-Ping Li, email: lijiaping_2011@126.com

Keywords: computer tomography, cryoablation, retroperitoneal sarcoma, survival, response rate

Received: October 10, 2015    Accepted: April 16, 2016    Published: May 19, 2016


Aims: To evaluate the use of computed tomography image-guided percutaneous cryoablation for recurrent retroperitoneal soft tissue sarcomas (RPSs).

Results: Adverse events were limited to grades 1 and 2, included fever (n = 19), local pain (n = 11), emesis (n = 10), frostbite (n = 6), and nerve injury (n = 1). Fever was more frequent in the large tumor group (15.8%) than in small tumor group (1.9%) (P = 0.008). Median PFS and OS were 37.0 ± 7.7 months (range, 4–39 months) and 43.0 ± 5.9 months (range, 6–54 months), respectively. PFS and OS were significantly longer in the small tumor group than in the large tumor group (P = 0.011 and P = 0.015, respectively), but the response rate (82.7% vs. 72.8%, P = 0.240) did not differ significantly. On univariate analysis, tumor size, tumor invasion grade, and distant metastasis were significant prognostic factors for PFS and OS. On multivariate analysis, a tumor size ≥10 cm was an independent negative prognostic factor for PFS and OS after cryoablation (HR: 3.98, 95% CI: 1.27–12.50, P = 0.018 and HR: 4.33, 95% CI: 1.41–13.26, P = 0.010, respectively).

Materials and Methods: Data from 72 patients with recurrent RPSs who underwent percutaneous cryoablation were reviewed retrospectively. The prognostic factors for progression-free survival (PFS), overall survival (OS), and efficacy based on mRECIST criteria were analysis. Adverse events were compared according to tumor size (<10 and ≥10 cm).

Conclusion: Minimally invasive percutaneous cryoablation was safe and efficacious for recurrent RPSs.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9476